IDEAS home Printed from https://ideas.repec.org/a/bla/ecaffa/v45y2025i3p461-478.html

Societal value and health economic benefits of GLP‐1 drugs in the United States

Author

Listed:
  • Frederik Cyrus Roeder
  • Emil Panzaru

Abstract

This article provides an overview of the health economics of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in the United States based on a selection of the key literature, with some comparison references to cost‐effectiveness in the United Kingdom. It discusses the potential health‐care cost savings and societal benefits of products such as semaglutide (Ozempic/Wegovy), followed by current pricing trends and coverage, concluding with methodological and policy implications. To correctly consider the greater positive effects of GLP‐1 agonists, standard methods of assessment must go beyond list prices and balance cost‐containment, equity, and access while preserving competition and choice in the health‐care market.

Suggested Citation

  • Frederik Cyrus Roeder & Emil Panzaru, 2025. "Societal value and health economic benefits of GLP‐1 drugs in the United States," Economic Affairs, Wiley Blackwell, vol. 45(3), pages 461-478, October.
    • Handle: RePEc:bla:ecaffa:v:45:y:2025:i:3:p:461-478
    DOI: 10.1111/ecaf.70011
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/ecaf.70011
    Download Restriction: no
    File URL: https://libkey.io/10.1111/ecaf.70011?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Mark Duggan & Fiona M. Scott Morton, 2006. "The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 121(1), pages 1-30.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2024. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," American Economic Review, American Economic Association, vol. 114(3), pages 615-644, March.
    2. Bradley T. Shapiro, 2016. "Estimating the cost of strategic entry delay in pharmaceuticals: The case of Ambien CR," Quantitative Marketing and Economics (QME), Springer, vol. 14(3), pages 201-231, September.
    3. Peter Grajzl & Stjepan Srhoj & Jaka Cepec & Barbara Mörec, 2024. "A by-product of big government: the attenuating role of public procurement for the effectiveness of grants-based entrepreneurship policy," Small Business Economics, Springer, vol. 62(3), pages 895-916, March.
    4. Antonio Cabrales & Sergi Jiménez‐Martín, 2013. "The Determinants Of Pricing In Pharmaceuticals: Are Us Prices Really So High?," Health Economics, John Wiley & Sons, Ltd., vol. 22(11), pages 1377-1397, November.
    5. Roger Bate & Ginger Zhe Jin & Aparna Mathur, 2012. "In Whom We Trust: The Role of Certification Agencies in Online Drug Markets," NBER Working Papers 17955, National Bureau of Economic Research, Inc.
    6. Marianne P. Bitler & Madeline Zavodny, 2014. "Medicaid: A Review of the Literature," NBER Working Papers 20169, National Bureau of Economic Research, Inc.
    7. Arvate, Paulo Roberto & Barbosa, Klênio & Gambardella, Dante, 2013. "Generic-branded drug competition and the price for pharmaceuticals in procurement auctions," Textos para discussão 333, FGV EESP - Escola de Economia de São Paulo, Fundação Getulio Vargas (Brazil).
    8. Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies 921, Umeå University, Department of Economics.
    9. Jena, Anupam B. & Philipson, Tomas J., 2013. "Endogenous cost-effectiveness analysis and health care technology adoption," Journal of Health Economics, Elsevier, vol. 32(1), pages 172-180.
    10. Mark Duggan & Patrick Healy & Fiona Scott Morton, 2008. "Providing Prescription Drug Coverage to the Elderly: America's Experiment with Medicare Part D," Journal of Economic Perspectives, American Economic Association, vol. 22(4), pages 69-92, Fall.
    11. Stamm, Andreas & Dietrich, Luise & Harling, Heike & Häußler, Laura & Münch, Florian & Preiß, Jana & Siebert, Jan, 2019. "Sustainable public procurement as a tool to foster sustainable development in Costa Rica: Challenges and recommendations for policy implementation," IDOS Studies, German Institute of Development and Sustainability (IDOS), volume 100, number 100.
    12. Brandyn F. Churchill & Laura E. Henkhaus & Emily C. Lawler, 2025. "Effect of vaccine recommendations on consumer and firm behavior," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 44(1), pages 125-150, January.
    13. Nancy L. Rose, 2014. "Learning from the Past: Insights for the Regulation of Economic Activity," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 1-23, National Bureau of Economic Research, Inc.
    14. Ridley, David B. & Zhang, Su, 2017. "Regulation of price increases," International Journal of Industrial Organization, Elsevier, vol. 50(C), pages 186-213.
    15. Blanchard, Pablo & Fleitas, Sebastian & González Valdenegro, Rodrigo, 2026. "Regulation by Public Options: Evidence from Pension Funds," CEPR Discussion Papers 21152, Centre for Economic Policy Research.
    16. Azoulay, Pierre & Heggeness, Misty & Kao, Jennifer, 2025. "Medical research and health care finance: Evidence from Academic Medical Centers," Research Policy, Elsevier, vol. 54(2).
    17. Alpert, Abby & Duggan, Mark & Hellerstein, Judith K., 2013. "Perverse reverse price competition: Average wholesale prices and Medicaid pharmaceutical spending," Journal of Public Economics, Elsevier, vol. 108(C), pages 44-62.
    18. Ziyad S. Almalki & Xiaomeng Yue & Ying Xia & Patricia R. Wigle & Jeff Jianfei Guo, 2017. "Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015," PharmacoEconomics - Open, Springer, vol. 1(2), pages 123-131, June.
    19. Lin Lin & Bo Wang, 2025. "Marketing Status and Brand‐Name Drug Prices: Evidence From Rx‐To‐OTC Switch," Health Economics, John Wiley & Sons, Ltd., vol. 34(6), pages 1064-1084, June.
    20. Cabiedes Miragaya, Laura, 2013. "Nuevas perspectivas sobre el precio de los medicamentos: El caso español/New Perspectives on Drug Pricing: The Spanish Case," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 31, pages 397-416, Septiembr.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:ecaffa:v:45:y:2025:i:3:p:461-478. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0265-0665 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.